Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingGlobeNewsWire • 04/10/24
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingGlobeNewsWire • 04/09/24
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023GlobeNewsWire • 11/14/23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsGlobeNewsWire • 11/07/23
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerGlobeNewsWire • 10/23/23
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023GlobeNewsWire • 09/27/23
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsGlobeNewsWire • 08/17/23
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023GlobeNewsWire • 08/15/23
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsGlobeNewsWire • 08/01/23
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewsWire • 06/05/23
Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/02/23
Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewsWire • 05/02/23
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingGlobeNewsWire • 04/21/23
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLGlobeNewsWire • 04/18/23
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLGlobeNewsWire • 04/18/23
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeGlobeNewsWire • 03/21/23
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 03/15/23
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS ConferenceGlobeNewsWire • 03/09/23
Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal MoleculesGlobeNewsWire • 03/08/23
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to StockholdersGlobeNewsWire • 02/01/23
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302GlobeNewsWire • 01/24/23
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate CommunicationsGlobeNewsWire • 01/23/23
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic CancerGlobeNewsWire • 01/10/23
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic PlatformGlobeNewsWire • 01/05/23